Skip to main content
Top
Published in:

01-05-2025 | Sarcoidosis | Case Based Review

Successful infliximab therapy in systemic sarcoidosis presenting with giant leg ulcers: a case based review

Authors: Nabil Belfeki, Nadia Ghariani Fetoui, Nour El Imene Ouni, Juliette Avci, Renaud Guedec-Ghelfi, Sonia Kammoun, Nouha Ghriss

Published in: Rheumatology International | Issue 5/2025

Login to get access

Abstract

Sarcoidosis is a chronic granulomatous inflammatory disease that primarily affects the lungs and skin. Cutaneous involvement occurs in approximately 30% of cases. We report herewith a rare case of a 55-year-old man with chronic, non-healing bilateral leg ulcers, ultimately diagnosed as ulcerative cutaneous sarcoidosis through histopathological confirmation. Giant leg ulcers complicating systemic sarcoidosis is rare and its management is challenging because there are no specific recommendation. In our case, a 24-month course of intravenous infliximab associated with oral prednisone induced sustained clinical remission. The current decline is three years. The aim of our work is to review the clinical presentation and management of ulcerative cutaneous sarcoidosis and compare them to reported cases in literature.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Successful infliximab therapy in systemic sarcoidosis presenting with giant leg ulcers: a case based review
Authors
Nabil Belfeki
Nadia Ghariani Fetoui
Nour El Imene Ouni
Juliette Avci
Renaud Guedec-Ghelfi
Sonia Kammoun
Nouha Ghriss
Publication date
01-05-2025
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 5/2025
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-025-05887-3

Keynote webinar | Spotlight on advances in lupus

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Learn more about novel biomarkers for diagnosis and monitoring, and familiarize yourself with current and emerging targeted therapies.

Prof. Edward Vital
Prof. Ronald F. van Vollenhoven
Developed by: Springer Medicine
Watch now

EULAR 2025

Explore the latest news and updates from the annual congress of the European Alliance of Associations for Rheumatology.

Read more